Christin Krause1, Helen Sievert1, Cathleen Geißler1, Martina Grohs1, Alexander T El Gammal2, Stefan Wolter2, Olena Ohlei3, Fabian Kilpert3, Ulrike M Krämer4,5, Meike Kasten6,7, Christine Klein6, Georg E Brabant1, Oliver Mann2, Hendrik Lehnert1,8, Henriette Kirchner1,8. 1. Medical Department I, Division Epigenetics & Metabolism, University of Lübeck, Lübeck, Germany. 2. Department of General, Visceral & Thoracic Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 3. Lübeck Interdisciplinary Platform for Genome Analytics, Institutes of Neurogenetics & Integrative & Experimental Genomics, University of Lübeck, Lübeck, Germany. 4. Department of Neurology, University of Lübeck, Lübeck, Germany. 5. Institute of Psychology II, University of Lübeck, Lübeck, Germany. 6. Institute of Neurogenetics, University of Lübeck, Lübeck, Germany. 7. Department of Psychiatry & Psychotherapy, University of Lübeck, Lübeck, Germany. 8. German Center for Diabetes Research (DZD), München-Neuherberg, Germany.
Abstract
Aim: Validation of epigenome-wide association studies is sparse. Therefore, we evaluated the methylation markers cg06500161 (ABCG1) and cg11024682 (SREBF1) as classifiers for diabetes stratification. Patients & methods: DNA methylation was measured in blood (n = 167), liver (n = 99) and visceral adipose tissue (n = 99) of nondiabetic or Type 2 diabetic subjects by bisulfite pyrosequencing. Results: DNA methylation at cg11024682 in blood and liver correlated with BMI. Methylation at cg06500161 was influenced by the adjacent SNP rs9982016. Insulin-resistant and sensitive subjects could be stratified by DNA methylation status in blood or visceral adipose tissue. Conclusion: DNA methylation at both loci in blood presents a promising approach for risk group stratification and could be valuable for personalized Type 2 diabetes risk prediction in the future.
Aim: Validation of epigenome-wide association studies is sparse. Therefore, we evaluated the methylation markers cg06500161 (ABCG1) and cg11024682 (SREBF1) as classifiers for diabetes stratification. Patients & methods: DNA methylation was measured in blood (n = 167), liver (n = 99) and visceral adipose tissue (n = 99) of nondiabetic or Type 2 diabetic subjects by bisulfite pyrosequencing. Results: DNA methylation at cg11024682 in blood and liver correlated with BMI. Methylation at cg06500161 was influenced by the adjacent SNP rs9982016. Insulin-resistant and sensitive subjects could be stratified by DNA methylation status in blood or visceral adipose tissue. Conclusion: DNA methylation at both loci in blood presents a promising approach for risk group stratification and could be valuable for personalized Type 2 diabetes risk prediction in the future.
Entities:
Keywords:
ABCG1; DNA methylation; EWAS; SREBF1; Type 2 diabetes; blood; liver; visceral adipose tissue
Authors: Monica Del C Gomez-Alonso; Anja Kretschmer; Rory Wilson; Liliane Pfeiffer; Ville Karhunen; Ilkka Seppälä; Weihua Zhang; Kirstin Mittelstraß; Simone Wahl; Pamela R Matias-Garcia; Holger Prokisch; Sacha Horn; Thomas Meitinger; Luis R Serrano-Garcia; Sylvain Sebert; Olli Raitakari; Marie Loh; Wolfgang Rathmann; Martina Müller-Nurasyid; Christian Herder; Michael Roden; Mikko Hurme; Marjo-Riitta Jarvelin; Mika Ala-Korpela; Jaspal S Kooner; Annette Peters; Terho Lehtimäki; John C Chambers; Christian Gieger; Johannes Kettunen; Melanie Waldenberger Journal: Clin Epigenetics Date: 2021-01-07 Impact factor: 6.551
Authors: Bertha A Hidalgo; Bre Minniefield; Amit Patki; Rikki Tanner; Minoo Bagheri; Hemant K Tiwari; Donna K Arnett; Marguerite Ryan Irvin Journal: PLoS One Date: 2021-11-15 Impact factor: 3.240
Authors: Sara Andrade; Tiago Morais; Ionel Sandovici; Alexandre L Seabra; Miguel Constância; Mariana P Monteiro Journal: Front Endocrinol (Lausanne) Date: 2021-06-29 Impact factor: 5.555
Authors: Zoe E Reed; Matthew J Suderman; Caroline L Relton; Oliver S P Davis; Gibran Hemani Journal: Clin Epigenetics Date: 2020-03-30 Impact factor: 6.551